| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer (NCT00365183) | Pharmacyclics LLC. | 2006-06-01 |
| Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NCT00090675) | AstraZeneca | 2006-01-01 |
| The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer (NCT00243347) | AstraZeneca | 2005-12-01 |
| Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer (NCT00129844) | Pharmacyclics LLC. | 2005-09-01 |
| Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT00124280) | Novartis Pharmaceuticals | 2005-07-01 |
| Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma (NCT00192829) | Rambam Health Care Campus | 2005-06-01 |
| Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer (NCT00111839) | EMD Serono | 2005-05-31 |
| Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients (NCT00271323) | Sanofi | 2005-05-01 |
| A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT00162318) | Eli Lilly and Company | 2005-03-01 |
| Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. (NCT00105092) | Eli Lilly and Company | 2005-03-01 |
| Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT00112346) | Eli Lilly and Company | 2005-01-01 |
| A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients (NCT00201825) | Tony Bekaii-Saab | 2004-12-01 |
| Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients. (NCT00181545) | Maastricht Radiation Oncology | 2004-12-01 |
| Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT00112294) | Eli Lilly and Company | 2004-12-01 |
| ZD6474 Phase IIa Dose Finding Multicentre Study (NCT00252746) | Genzyme, a Sanofi Company | 2004-12-01 |
| Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy (NCT00100932) | Eisai Inc. | 2004-12-01 |
| BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer (NCT00098254) | National Cancer Institute (NCI) | 2004-12-01 |
| A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) (NCT00102505) | Pharmacyclics LLC. | 2004-11-01 |
| Celecoxib Treatment for Lung Cancer (NCT00108186) | US Department of Veterans Affairs | 2004-10-01 |
| A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT00091663) | Genentech, Inc. | 2004-08-01 |
| Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial) (NCT00136864) | Ontario Clinical Oncology Group (OCOG) | 2004-08-01 |
| A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) (NCT00095225) | Genentech, Inc. | 2004-07-01 |
| Phase II Iressa Versus Vinorelbine (INVITE) (NCT00256711) | AstraZeneca | 2004-07-01 |
| A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (NCT00087711) | Eli Lilly and Company | 2004-07-01 |
| FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma (NCT00086333) | Seagen Inc. | 2004-07-01 |
| Non-small Cell Lung Cancer Study US75 (Z-PACT) (NCT00086268) | Novartis Pharmaceuticals | 2004-04-01 |
| Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer. (NCT00191620) | Eli Lilly and Company | 2004-03-01 |
| Iressa Versus Docetaxel (Taxotere) (NCT00076388) | AstraZeneca | 2004-02-01 |
| Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC (NCT00234468) | AstraZeneca | 2004-01-01 |
| Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma (NCT00078455) | Genzyme, a Sanofi Company | 2003-12-01 |
| Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients (NCT00213798) | University Hospital, Strasbourg, France | 2003-12-01 |
| Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer (NCT00081315) | MedImmune LLC | 2003-11-01 |
| Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer (NCT00098085) | Agenus Inc. | 2003-09-01 |
| Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer (NCT00199758) | University Hospital, Limoges | 2003-09-01 |
| Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301) (NCT00132665) | Japan Clinical Oncology Group | 2003-07-01 |
| Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC (NCT00181532) | Maastricht Radiation Oncology | 2003-05-01 |
| ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer (NCT00056537) | Active Biotech AB | 2003-04-01 |
| Chemoradiotherapy in Patients With Localised Lung Cancer (NCT00193921) | Trans Tasman Radiation Oncology Group | 2003-02-01 |
| Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients (NCT00137800) | Dana-Farber Cancer Institute | 2003-02-01 |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer (NCT00252798) | AstraZeneca | 2002-07-01 |
| Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. (NCT00148395) | Aktion Bronchialkarzinom e.V. | 2002-06-01 |
| Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies (NCT00037817) | National Cancer Institute (NCI) | 2002-05-17 |
| Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) (NCT00310232) | Ontario Clinical Oncology Group (OCOG) | 2001-02-01 |
| LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer (NCT00260598) | University of Pittsburgh | 1998-08-01 |
| Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT00080340) | Telik | |
| Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer (NCT00067548) | Wyeth is now a wholly owned subsidiary of Pfizer | |